Search
oprelvekin [IL-11] (Neumega)
Tradename: Neumega.
Indications:
1) prevention of thrombocytopenia in cancer patients
2) reduction in need for platelet transfusion following myelosuppressive chemotherapy
Dosage:
- 50 ug/kg/day SC, 75 ug/kg/day SC in pediatric patients Injectable: 5 mg preservative-free vials
Pharmacokinetics: Elimination: 1st order. 1/2 life 7 hours
Adverse effects:
1) water retention & edema
2) nausea/vomiting
3) fever
General
biological response modifier; immune factor; immunomodulator; biomodulator
interleukin-11; IL-11; adipogenesis inhibitory factor; AGIF; oprelvekin (IL11)